Adaptive Biotechnologies (ADPT) Set to Announce Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) is scheduled to be posting its quarterly earnings results on Tuesday, April 2nd.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last announced its earnings results on Wednesday, February 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. The business had revenue of $45.78 million during the quarter, compared to analysts’ expectations of $50.15 million. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Up 11.1 %

Shares of ADPT stock opened at $3.21 on Monday. Adaptive Biotechnologies has a fifty-two week low of $2.61 and a fifty-two week high of $9.08. The stock has a market capitalization of $465.74 million, a P/E ratio of -2.06 and a beta of 1.27. The stock has a 50-day simple moving average of $3.70 and a 200 day simple moving average of $4.33.

Insider Buying and Selling

In other news, insider Kyle Piskel sold 7,727 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $26,503.61. Following the completion of the sale, the insider now directly owns 123,318 shares of the company’s stock, valued at approximately $422,980.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, President Julie Rubinstein sold 39,070 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.47, for a total transaction of $135,572.90. Following the transaction, the president now owns 472,754 shares of the company’s stock, valued at approximately $1,640,456.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kyle Piskel sold 7,727 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $26,503.61. Following the transaction, the insider now directly owns 123,318 shares in the company, valued at approximately $422,980.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,307 shares of company stock valued at $428,090. Corporate insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ADPT. Point72 Middle East FZE acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at approximately $26,000. Meeder Asset Management Inc. grew its holdings in Adaptive Biotechnologies by 407.8% in the 4th quarter. Meeder Asset Management Inc. now owns 5,632 shares of the company’s stock valued at $43,000 after buying an additional 4,523 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Adaptive Biotechnologies by 23.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,432 shares of the company’s stock valued at $57,000 after buying an additional 1,587 shares during the last quarter. GTS Securities LLC acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at approximately $72,000. Finally, Townsquare Capital LLC acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at approximately $81,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group decreased their price target on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

View Our Latest Stock Analysis on Adaptive Biotechnologies

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Recommended Stories

Earnings History for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.